Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Totally Implantable Active Middle Ear Implants.

Seidman MD, Janz TA, Shohet JA.

Otolaryngol Clin North Am. 2019 Apr;52(2):297-309. doi: 10.1016/j.otc.2018.11.011. Epub 2019 Feb 12. Review.

PMID:
30770176
2.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

3.

Totally implantable active middle ear implant: Hearing and safety results in a large series.

Shohet JA, Gende DM, Tanita CS.

Laryngoscope. 2018 Dec;128(12):2872-2878. doi: 10.1002/lary.27246. Epub 2018 Sep 8.

PMID:
30194720
4.

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Eveline B, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Jul 6;9(52):30024. doi: 10.18632/oncotarget.25776. eCollection 2018 Jul 6.

5.

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barbieri E, Koster J, Perini G, Coarfa C, Shohet JM.

Oncotarget. 2018 Apr 17;9(29):20323-20338. doi: 10.18632/oncotarget.24859. eCollection 2018 Apr 17. Erratum in: Oncotarget. 2018 Jul 6;9(52):30024. Eveline, Barberi [corrected to Eveline, Barbieri].

6.

A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.

Curtin C, Nolan JC, Conlon R, Deneweth L, Gallagher C, Tan YJ, Cavanagh BL, Asraf AZ, Harvey H, Miller-Delaney S, Shohet J, Bray I, O'Brien FJ, Stallings RL, Piskareva O.

Acta Biomater. 2018 Apr 1;70:84-97. doi: 10.1016/j.actbio.2018.02.004. Epub 2018 Feb 12.

7.

Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.

Tomolonis JA, Agarwal S, Shohet JM.

Cell Tissue Res. 2018 May;372(2):245-262. doi: 10.1007/s00441-017-2747-0. Epub 2017 Dec 8. Review.

8.

EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.

Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG.

Oncotarget. 2017 Oct 19;8(55):94780-94792. doi: 10.18632/oncotarget.21933. eCollection 2017 Nov 7.

9.

Plasma-Generated OH Radical Production for Analyzing Three-Dimensional Structure in Protein Therapeutics.

Minkoff BB, Blatz JM, Choudhury FA, Benjamin D, Shohet JL, Sussman MR.

Sci Rep. 2017 Oct 11;7(1):12946. doi: 10.1038/s41598-017-13371-7.

10.

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T.

Oncotarget. 2017 Jul 4;8(34):57047-57057. doi: 10.18632/oncotarget.18982. eCollection 2017 Aug 22.

11.

p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.

Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E.

Clin Cancer Res. 2017 Nov 1;23(21):6629-6639. doi: 10.1158/1078-0432.CCR-17-0668. Epub 2017 Aug 18.

12.

Neuroblastoma.

Shohet J, Foster J.

BMJ. 2017 May 3;357:j1863. doi: 10.1136/bmj.j1863. No abstract available.

PMID:
28468760
13.

Totally implantable hearing system: Five-year hearing results.

Shohet JA, Kraus EM, Catalano PJ, Toh E.

Laryngoscope. 2018 Jan;128(1):210-216. doi: 10.1002/lary.26602. Epub 2017 Apr 13.

PMID:
28407310
14.

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples.

Van Goethem A, Yigit N, Everaert C, Moreno-Smith M, Mus LM, Barbieri E, Speleman F, Mestdagh P, Shohet J, Van Maerken T, Vandesompele J.

Sci Rep. 2016 Nov 30;6:37876. doi: 10.1038/srep37876.

15.

Heterogeneous Uptake of Nanoparticles in Mouse Models of Pediatric High-Risk Neuroblastoma.

Ghaghada KB, Starosolski ZA, Lakoma A, Kaffes C, Agarwal S, Athreya KK, Shohet J, Kim E, Annapragada A.

PLoS One. 2016 Nov 18;11(11):e0165877. doi: 10.1371/journal.pone.0165877. eCollection 2016.

16.

CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.

Zage PE, Whittle SB, Shohet JM.

J Cell Biochem. 2017 Feb;118(2):221-231. doi: 10.1002/jcb.25656. Epub 2016 Aug 16. Review.

PMID:
27428599
17.

Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma.

Agarwal S, Ghosh R, Chen Z, Lakoma A, Gunaratne PH, Kim ES, Shohet JM.

Oncotarget. 2016 Apr 26;7(17):24018-26. doi: 10.18632/oncotarget.8116.

18.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

19.

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.

Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J.

Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208.

20.

Reactivation of p53 via MDM2 inhibition.

Kim ES, Shohet JM.

Cell Death Dis. 2015 Oct 22;6:e1936. doi: 10.1038/cddis.2015.302. No abstract available.

21.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

22.

G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response.

Kim ES, Agarwal S, Shohet JM.

Cancer Res. 2015 Sep 15;75(18):3992. doi: 10.1158/0008-5472.CAN-15-1599. Epub 2015 Sep 3. No abstract available.

23.

NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.

Shi Y, Ma IT, Patel RH, Shang X, Chen Z, Zhao Y, Cheng J, Fan Y, Rojas Y, Barbieri E, Chen Z, Yu Y, Jin J, Kim ES, Shohet JM, Vasudevan SA, Yang J.

Cell Death Dis. 2015 Aug 6;6:e1841. doi: 10.1038/cddis.2015.207.

24.

CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.

Zhang L, Agarwal S, Shohet JM, Zage PE.

Anticancer Res. 2015 Jul;35(7):3787-92.

PMID:
26124323
25.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

26.

The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.

Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, Qu C, Nathwani AC, Shohet JM, Fotsis T, Koster J, Versteeg R, Okada H, Harris AL, Davidoff AM.

J Natl Cancer Inst. 2015 Apr 29;107(6):djv080. doi: 10.1093/jnci/djv080. Print 2015 Jun.

27.

G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM.

Cancer Res. 2015 Jun 15;75(12):2566-79. doi: 10.1158/0008-5472.CAN-14-2946. Epub 2015 Apr 23.

28.

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma.

Rihani A, Van Goethem A, Ongenaert M, De Brouwer S, Volders PJ, Agarwal S, De Preter K, Mestdagh P, Shohet J, Speleman F, Vandesompele J, Van Maerken T.

Sci Rep. 2015 Mar 12;5:9027. doi: 10.1038/srep09027.

29.

WIP1 phosphatase as a potential therapeutic target in neuroblastoma.

Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA, Kumar R.

PLoS One. 2015 Feb 6;10(2):e0115635. doi: 10.1371/journal.pone.0115635. eCollection 2015.

30.

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.

Lakoma A, Barbieri E, Agarwal S, Jackson J, Chen Z, Kim Y, McVay M, Shohet JM, Kim ES.

Cell Death Discov. 2015;1. pii: 15026. Epub 2015 Aug 24.

31.

Neuroblastoma: molecular pathogenesis and therapy.

Louis CU, Shohet JM.

Annu Rev Med. 2015;66:49-63. doi: 10.1146/annurev-med-011514-023121. Epub 2014 Oct 27. Review.

32.

The Envoy Esteem implantable hearing system.

Marzo SJ, Sappington JM, Shohet JA.

Otolaryngol Clin North Am. 2014 Dec;47(6):941-52. doi: 10.1016/j.otc.2014.08.006. Epub 2014 Sep 23. Review.

PMID:
25256656
33.

In vivo Lineage-tracing Studies in a Cancer Stem Cell Population in Neuroblastoma.

Hsu DM, Shohet JM, Kim ES.

Bio Protoc. 2014 Apr 20;4(8). pii: e1104.

34.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

35.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
36.

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma.

Barbieri E, De Preter K, Capasso M, Johansson P, Man TK, Chen Z, Stowers P, Tonini GP, Speleman F, Shohet JM.

PLoS One. 2013 Nov 19;8(11):e79843. doi: 10.1371/journal.pone.0079843. eCollection 2013.

37.

Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma.

Barbieri E, De Preter K, Capasso M, Chen Z, Hsu DM, Tonini GP, Lefever S, Hicks J, Versteeg R, Pession A, Speleman F, Kim ES, Shohet JM.

Cancer Res. 2014 Feb 1;74(3):765-74. doi: 10.1158/0008-5472.CAN-13-1315. Epub 2013 Dec 12.

38.

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.

Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES, Yang J.

Cell Death Dis. 2013 Oct 17;4:e867. doi: 10.1038/cddis.2013.400.

39.

Normative data of incus and stapes displacement during middle ear surgery using laser Doppler vibrometry.

Seidman MD, Standring RT, Ahsan S, Marzo S, Shohet J, Lumley C, Verzal K.

Otol Neurotol. 2013 Dec;34(9):1719-24. doi: 10.1097/MAO.0b013e3182976528.

PMID:
23928515
40.

G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, Stowers PN, Courtney AN, Lakoma A, Barbieri E, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM.

Cancer Res. 2013 Jul 1;73(13):4134-46. doi: 10.1158/0008-5472.CAN-12-4056. Epub 2013 May 16.

41.

Redefining functional MYCN gene signatures in neuroblastoma.

Shohet JM.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19041-2. doi: 10.1073/pnas.1217598109. Epub 2012 Nov 8. No abstract available.

42.

A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells.

Ghosh R, Singh LC, Shohet JM, Gunaratne PH.

Biomaterials. 2013 Jan;34(3):807-16. doi: 10.1016/j.biomaterials.2012.10.023. Epub 2012 Oct 27.

PMID:
23111335
43.

Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.

Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, Chen JB, Raif A, Jankowski K, Davies NP, Bekkum MV, Chen B, Tan O, Ellis T, Norris MD, Haber M, Kim ES, Shohet JM, Trahair TN, Liu T, Wainwright BJ, Ding HF, Marshall GM.

Oncogene. 2013 Aug 1;32(31):3616-26. doi: 10.1038/onc.2012.368. Epub 2012 Aug 20.

PMID:
22907436
44.

Profound high-frequency sensorineural hearing loss treatment with a totally implantable hearing system.

Shohet JA, Kraus EM, Catalano PJ.

Otol Neurotol. 2011 Dec;32(9):1428-31. doi: 10.1097/MAO.0b013e3182382bc8.

PMID:
22072264
45.

Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery.

Patterson DM, Shohet JM, Kim ES.

Curr Protoc Pharmacol. 2011 Mar;Chapter 14:Unit 14.17. doi: 10.1002/0471141755.ph1417s52.

PMID:
21935903
46.

A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.

Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH.

Cancer Res. 2011 Jun 1;71(11):3841-51. doi: 10.1158/0008-5472.CAN-10-4391. Epub 2011 Apr 15.

47.

Envoy Esteem Totally Implantable Hearing System: phase 2 trial, 1-year hearing results.

Kraus EM, Shohet JA, Catalano PJ.

Otolaryngol Head Neck Surg. 2011 Jul;145(1):100-9. doi: 10.1177/0194599811401709.

PMID:
21493292
48.

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.

Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.

PMID:
21484514
49.

Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma.

Russell H, Shohet JM.

Nat Rev Clin Oncol. 2011 Jan;8(1):6-8. doi: 10.1038/nrclinonc.2010.195. Epub 2010 Nov 23. No abstract available.

PMID:
21102531
50.

Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.

Shang X, Vasudevan SA, Yu Y, Ge N, Ludwig AD, Wesson CL, Wang K, Burlingame SM, Zhao YJ, Rao PH, Lu X, Russell HV, Okcu MF, Hicks MJ, Shohet JM, Donehower LA, Nuchtern JG, Yang J.

Oncogene. 2010 Sep 2;29(35):4938-46. doi: 10.1038/onc.2010.244. Epub 2010 Jun 21.

PMID:
20562916

Supplemental Content

Loading ...
Support Center